




IV INTERNATIONAL THORACIC CANCER DEBATES

30 - 31 January, 2026

Auditorio Alfredo Kraus, Las Palmas de Gran Canaria



#ITCD2026  

SCIENTIFIC COORDINATORS

Dr. Rosario García Campelo

Hospital Univ. A Coruña

Dr. Luis Paz-Ares

Hospital Univ. 12 de Octubre. Madrid

Dr. Stephen Liu

Lombardi Cancer Center Georgetown University, Washington, USA

Dr. Delvys Rodríguez Abreu

Hospital Univ. Insular, Las Palmas de Gran Canaria

Organized by

FCCCP
FUNDACIÓN CANARIA
DE CÁNCER DE PULMÓN

Welcome to #itcd2026

International Thoracic Cancer Debates 2026 brings together international specialists to present and discuss recent scientific developments, assess therapeutic strategies and review clinical cases in a scientifically stimulating and open environment.

Thank you for joining us at ITCD 2026, guided by the theme:
Redefining the Limits of Lung Cancer. Shaping Meaningful Progress.

Under the auspices of



Institutional support



Credits



International Thoracic Cancer Debates 2026 cuenta con el Reconocimiento de Interés Sanitario para actos de carácter científico de la Consejería de Sanidad del Gobierno de Canarias.



Solicitada la acreditación como Formación Continuada de las Profesiones Sanitarias de la Comunidad Autónoma de Canarias. Se requerirá la asistencia presencial al evento. Se excluye del sistema acreditador a estudiantes y médicos internos residentes.

General information



language: English



Venue: Palácio de Congreso Auditorio Alfredo Kraus. Sala Cámara. Ctra. del Rincón, s/n, 35010 Las Palmas de Gran Canaria, Las Palmas



Technical secretary: SILK Marketing
Tel: 682 42 73 40
Mail: gccpsectec@silkmarketing.es
www.silkmarketing.es

Friday 30

8:15  **Registration opening**

8:55-9:10 **Welcome and official opening**

9:10-9:30 **Lecture: SCLC from biology to future?**

Keynote: Dr. Luis Paz-Ares. Hospital Univ. 12 de Octubre. Madrid

Chair: Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

9:30-9:40  **Discussion**

SESSION 1

Friday 30 morning

Duration of the session

9:40 - 11:05

Early stages with AGAs NSCLC

Chairs: Dr. Pilar Garrido. Hospital Univ. Ramón y Cajal, Madrid

Dr. Edgardo Santos. The Oncology Institute of Hope and Innovation, Florida, USA

Early stage: neoadjuvant and adjuvant

9:40 - 9:55 **In EGFRm NSCLC: Neoadjuvant or Adjuvant therapy or both.?**

Dr. Narjust Florez. Dana-Farber Cancer Institute, Boston, USA

9:55 - 10:10 **What about ALK and others?**

Dr. Lorenza Landi. Regina Elena National Cancer Institute, Rome, Italy

10:10 - 10:25 **Challenges of using and adapting MRD in lung cancer**

Dr. Luis E. Raez. Memorial Cancer Institute at Memorial Healthcare System, Florida, USA

10:25 - 11:05  **Panel Discussion**

Dr. Margarita Majem. Hospital de la Santa Creu i Sant Pau. Barcelona

Dr. Ernest Nadal. ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona

Dr. Enric Carcereny. ICO, Hospital Univ. Germans Trias i Pujol, Badalona, Barcelona

Dr. Edgardo Santos. The Oncology Institute of Hope and Innovation, Florida, USA

11:05 - 11:30



COFFEE BREAK

Duration of the session

Advanced stage 1st line with AGAs

 Chairs: Dr. Rosario García Campelo. Hospital Univ. A Coruña
 Dr. Rafael Rosell. Hospital Univ. Dexeus, Barcelona

11:30 – 11:45

Advanced EGFRm: which combo/ which patient?

Dr. Daniel Tan. National Cancer Centre Singapore

11:45 – 12:00

From Success to Resistance: Managing Progression in EGFR-Mutant Lung Cancer

Dr. Pasi Jänne. Dana-Farber Cancer Institute, Boston, USA

12:00 – 12:15

Exon 20 insertions. Not so uncommon disease but different treatments?

Dr. Noemi Reguart. Hospital Clinic Barcelona

12:15 – 12:30

HER2 deregulated NSCLC. ADC or TKIs treatment?

Dr. Rosario García Campelo, Hospital Univ. A Coruña

12:30 – 12:45

KRAS which one is the winning strategics in the future

Dr. Jordi Remon. Institute Gustave Roussy, Paris, France

12:45 – 13:25

Panel Discussion. All the authors

Dr. Noemi Reguart. Hospital Clinic Barcelona

Dr. Antonio Calles. Hospital General Univ. Gregorio Marañón, Madrid

Dr. Oscar Juan. Hospital Univ. y Politécnico La Fe, Valencia

Dr. Reyes Bernabé. Hospital Univ. Virgen del Rocío, Sevilla

13:25 – 14:10


LUNCH BREAK

SESSION 2

Friday 30 afternoon

Duration of the session

14:10 – 15:35

Metastatic NSCLC other mutations

 Chairs: Dr. Bartomeu Massuti. Hospital General Univ. Dr. Balmis, Alicante
 Dr. Javier de Castro. Hospital Univ. La Paz, Madrid

14:10 – 14:25

How to move forward from CROWN in ALK+ NSCLC?

Dr. Tony Mok. Chinese University of Hong Kong, Hong Kong SAR, China

14:25 – 14:40

News in the ROS1 and RET world.

Dr. Jessica Lin. Massachusetts General Brigham Cancer Institute, USA

14:40 – 14:55

NTRK, BRAF and MET + NSCLC. What is new?

Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

14:55 – 15:35

Panel Discussion

Dr. Martín Lázaro. Hospital Álvaro Cunqueiro, Vigo

Dr. Santiago Víteri. UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona

Dr. Dolores Isla. Hospital Univ. Lozano Blesa, Zaragoza

Dr. Emilio Esteban. Hospital Universitario Central de Asturias

15:35 – 15:50


COFFEE BREAK

SESSION 3

Friday 30 afternoon

Duration of the session
15:50 - 17:15

IMMUNOTHERAPY IN NSCLC. Localize disease

Chairs: Dr. Luis Paz-Ares. Hospital Univ. 12 de Octubre. Madrid
 Dr. Edgardo Santos. The Oncology Institute of Hope and Innovation, Florida, USA

15:50 - 16:05

The Path to lung cancer cure. What is beyond the traditional approaches?

Dr. Federico Cappuzzo. Regina Elena National Cancer Institute, Rome, Italy

16:05 - 16:20

Expanding/Redefining the role of surgery in IO era

Dr. Cecilia Pompili. University of Hull, United Kingdom

16:20 - 16:35

Any new real IO biomarkers on scene

Dr. Sanjay Popat. Royal Marsden Hospital, London, United Kingdom

16:35 - 17:15

Panel Discussion

Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece
 Dr. José Ramón Cano. Hospital Univ. Insular, Las Palmas de Gran Canaria
 Dr. Sergio Vázquez. Hospital Univ. Lucus Augusti, Lugo
 Dr. Jesús Corral. Hospital Univ. de Jerez de la Frontera, Cádiz

SESSION 4

Friday 30 afternoon

Duration of the session
17:15 - 18:00

Economic and Technological Perspectives in Lung Cancer

Chairs: Dr. D. Lluís Serra Majem. Rector Magnífico Univ. de Las Palmas de Gran Canaria
 PH.D. Beatriz González López-Valcárcel. Univ. de Las Palmas de Gran Canaria

17:15 - 17:30

The economic unfeasibility of personalized medicine in Lung cancer

PH.D. Pietro Veronesi. University of Chicago, USA

17:30 - 17:45

AI agent for healthcare: from usability to sustainability

Dr. Arsela Prelaj. IRCCS National Cancer Institute Foundation of Milan, Italy

17:45 - 18:00

Discussion

18:00 **CLOSING**

Saturday 31

SESSION 5

Saturday 31 morning

 Duration of the session
9:30 - 10:30
Small cell carcinoma

 Chairs: Dr. Rolf Stahel. ETOP IBCSG Partners Foundation, Berne, Switzerland
 Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece

09:30 - 09:45

Relapsed SCLC: Breaking the Limits, Redefining Boundaries

Dr. Giannis Mountzios. Henry Dunant Hospital Center. Athens, Greece

9:45 - 10:00

Redefining the front-line standards in SCLC

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

10:00-10:15

Re-thinking Limited-Stage SCLC: Is a paradigm shift finally here?

Dr. Jarushka Naidoo. Beaumont RCSI Cancer Centre, Dublin, Ireland

10:15 - 10:30


Discussion and Q&A

 Dr. José Manuel Trigo. Hospital HC Marbella, Malaga
 Dr. Manuel Domine. IIS-FJD. Oncohealth Institute, Madrid
 Dr. Anna Estival. Hospital Univ. Insular, Las Palmas de Gran Canaria

10:30 - 10:50


COFFEE BREAK

SESSION 6

Saturday 31 morning

 Duration of the session
10:50 - 11:50
ADCs double molecules

 Chairs: Dr. Delvys Rodríguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria
 Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

10:50 - 11:05

What is the right place for anti Trop2 ADCs

Dr. Marina Garassino. University of Chicago, Chicago

11:05 - 11:20

Emerging ADCs. New generations?

Dr. Martin Reck. LungenClinic Grosshansdorf, Hamburg, Germany

11:20 - 11:35

Cell Therapy, CAR T and vaccines

Dr. Jon Zugazagoitia. Hospital Univ. 12 de Octubre, Madrid

11:35 - 11:50


Discussion and Q&A

 Dr. Anna Estival. Hospital Univ. Insular, Las Palmas de Gran Canaria
 Dr. Manuel Cobo. Hospital Regional Univ. de Málaga
 Dr. Ana Laura Ortega Granados. Hospital Univ. de Jaén, Andalucía
 Dr. Ignacio Gil Bazo. Hospital Quirónsalud Zaragoza

SESSION 7

Saturday 31 morning

Duration of the session
11:50 - 13:05

Bispecific. doubles the future

Chairs: Dr. Santiago Ponce. Hospital Univ. 12 de Octubre, Madrid
Dr. Luis Ángel León. Hospital Clínico Univ. Santiago de Compostela

11:50 - 12:05

Biology, why is the sum greater than its parts?

Dr. Jair Bar. Sheba Medical Center, Israel

12:05 - 12:20

Knocking on Two Doors: BsAbs Modulating Immune Checkpoints in NSCLC

Dr. Solange Peters. Univ. Hospital of Lausanne, Switzerland

12:20 - 12:35

Bispecific Antibodies That Starve and Activate: PD-1 and VEGF Dual Blockade

Dr. Delvys Rodríguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria

12:35 - 12:50

Management of emerging toxicities (ADC, bispecific and T-cell engager)

Dr. Arancha Manzano. Hospital Univ. 12 de Octubre. Madrid

12:50 - 13:05

Panel Discussion

Dr. Antonio Araujo. Hospital Univ. Oporto, Portugal
Dr. Pilar Garrido. Hospital Univ. Ramón y Cajal, Madrid
Dr. Oscar Juan. Hospital Univ. Politécnico La Fe, Valencia

13:05 - 13:15

CLOSING REMARKS

Gold



Johnson & Johnson

Silver



AstraZeneca



Bronze

Bristol Myers Squibb™

REGENERON
SCIENCE TO MEDICINE®



BeOne

AMGEN®

Collaborators

Lilly

LABORATOIRES
Pierre Fabre

OSE IMMUNO
THERAPEUTICS



Summit
Therapeutics

MERCK

Boehringer
Ingelheim

Daiichi-Sankyo

AstraZeneca

ZarapicoMed

Secretaría Técnica

Silk